NewsBenzingaVerastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026 Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026 Benzinga 2026.10.02 11:32 (GMT+0) Open on Benzinga Other news Earnings Preview: What to Expect From Mosaic’s Report Gartner’s Q3 2026 Earnings: What to Expect Global Payments’ Quarterly Earnings Preview: What You Need to Know Earnings Preview: What to Expect From Assurant Report What a New Nvidia-Backed AI Platform Means for Honeywell Stock What You Need to Know Ahead of Yum! Brands' Earnings Release
